Blockchain Registration Transaction Record
Clene Announces Q1 2025 Financial Results and Progress on CNM-Au8 Program for ALS and MS
Clene announces first quarter 2025 financial results and updates on CNM-Au8 program for ALS and MS. Progress towards potential FDA approval and positive clinical trial results signify a significant step forward in neurodegenerative disease research.

This news matters as Clene's advancements in developing therapies for neurodegenerative diseases like ALS and MS could potentially lead to improved treatment options for patients. The company's progress towards potential FDA approval and positive clinical trial results signify a significant step forward in the field of neurodegenerative disease research.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0x1d4e99b1712e6259caaf159938baf0febc7599df08142586c5d87de9230c875f |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | fineticz-bfeac99f67382a02dea42e0d535e7e07 |